Table 2 Demographics and clinical characteristics of AML patients according to ASCs ratio

N

27

33

Male/Female

14/13

14/19

0.466

Age, years

Min

15

16

0.471

Max

81

82

Median (SD)

49 (3.2)

58 (3.2)

0.724

M0

2 (7.4)

1 (3.0)

M1

3 (11.1)

2 (6.1)

M2

15 (55.6)

19 (57.6)

M4

6 (22.2)

7 (21.2)

M5

1 (3.7)

2 (6.1)

M6

0 (0.0)

2 (6.1)

Cytogenetics, N (%)^*

0.621

Favorable

9 (33.3)

9 (27.3)

Intermediate

16 (59.3)

19 (57.6)

Unfavorable

2 (7.4)

5 (15.2)

CD34% groups, N (%)

0.031

%CD34+ <5

2 (7.4)

7 (21.2)

5 ≤ %CD34+ <20

3 (11.1)

10 (30.3)

20 ≤ %CD34+

22 (81.5)

16 (48.5)

WBC (*1000/uL)

Median

30.1

25.2

0.379

PLT (*1000/uL)

Median

37

44

0.698

Hemoglobin (g/dL)

Median

8.5

8.2

0.871

BM blast, %

Median

73

60

0.078

Expired case, N (%)

9 (33.3)

16 (48.5)

0.236

Relapse case, N (%)

14 (51.9)

17 (51.5)

0.979

Median overall survival, months

12

7

0.211

Median relapse free survival, months

7

6

0.442